Encouraging updated preliminary survival data more than double standard of care reported in relapsed AML patients
BERGEN, Norway, June 11, 2021 /PRNewswire/ — BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
